Last Updated on October 17, 2024 by The Health Master
Shilpa Medicare has received 15 observations from US Food and Drug Administration (FDA) for the company’s finished dosage formulation facility (sterile and non-sterile) for Jadcherla facility.
“US FDA conducted good manufacturing practices (GMP) inspection of the company’s finished dosage formulation facility (sterile and non-sterile) from 13-25, February 2020,” the company said in a BSE filing.
The facility is located at S-20 to S-26, pharmaceutical formulations SEZ, TSIIC, Jadcherla, Telangana State, India.
Also read: Alkem Labs gets two USFDA observations
The company is preparing responses to the observations, which will be submitted to the agency within 15 business days.
The company is committed to addressing these observations promptly.
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
